Table of Contents Author Guidelines Submit a Manuscript
Advances in Pharmacological Sciences
Volume 2014 (2014), Article ID 132034, 6 pages
Research Article

Teratogenic Effects of Coadministration of Fluoxetine and Olanzapine on Rat Fetuses

1Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Pour Sina Street, Qods Street, Keshavarz Boulevard, Tehran 1417613151, Iran
2Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613146, Iran
3School of Medicine, Tehran University of Medical Sciences, Tehran 1417613110, Iran
4Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
5Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Pisa 56122, Italy

Received 30 September 2013; Revised 25 November 2013; Accepted 16 December 2013; Published 16 January 2014

Academic Editor: Todd C. Skaar

Copyright © 2014 Azam Bakhtiarian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. Depression during pregnancy is a relatively common problem. Since little is known about the teratogenic effects of concomitant administration of fluoxetine and olanzapine during the organogenesis period, the aim of the present study was to evaluate the teratogenic effects of coadministration of fluoxetine and olanzapine on rat fetuses. Method. Forty-two pregnant rats were divided into seven groups, randomly. The first group received 0.5 mL of normal saline as the control. The second and third groups received fluoxetine at doses of 9 mg/kg and 18 mg/kg, respectively. Olanzapine was injected at 3 mg/kg and 6 mg/kg to the fourth and fifth groups, respectively. The sixth group received 9 mg/kg fluoxetine and 3 mg/kg olanzapine. Finally, the seventh group was administrated with fluoxetine and olanzapine at 18 mg/kg and 6 mg/kg, respectively. Drugs were injected intraperitoneally between day eight and day 15 of the pregnancy. On the 17th day of pregnancy, the fetuses were removed and micro-/macroscopically studied. Results. Fetuses of rats receiving high doses of these drugs showed a significant rate of cleft palate development, premature eyelid opening and torsion anomalies, compared to the control group ( ). It is concluded that these drugs can lead to teratogenicity, so their concomitant use during pregnancy should be avoided, or if necessary their doses must be decreased.